In a whirlwind of current events, allegations arise about Iranian hackers targeting a U.S. presidential campaign. A tragic Israeli airstrike hits a Gaza school, prompting outrage and calls for accountability. Chilling footage from the Uvalde shooting resurfaces, igniting discussions on transparency. On a lighter note, Tom Cruise steals the show at the Paris Olympics closing ceremonies, giving fans a reason to reflect on the unforgettable moments of the Games. It's a blend of political intrigue and cultural highlights all in one.
The Trump campaign has been targeted by Iranian hackers, raising concerns about foreign interference in the upcoming elections.
A newly approved nasal spray for allergic reactions offers a needle-free option, aiming to improve treatment accessibility for needle-averse individuals.
Deep dives
Trump Campaign Hacked by Iranian Hackers
Evidence has emerged indicating that the Trump campaign was targeted by Iranian hackers. Microsoft reported attempts to breach the email account of a high-ranking official within the campaign, which reportedly occurred in June. The breach involved a confidential vetting document regarding Trump's running mate, Senator JD Vance, alongside a lengthy document that aggregated publicly available information about him. This incident raises concerns among analysts and intelligence experts about potential foreign efforts to disrupt the upcoming November elections.
FDA Approves Needle-Free Allergy Treatment
A new nasal spray designed for treating serious allergic reactions has gained FDA approval, offering a needle-free alternative to conventional options like the EpiPen. This spray, called nefi, administers epinephrine through the nasal cavity and is particularly aimed at individuals who may avoid treatment due to a fear of needles. The FDA believes this innovation could benefit many, especially children, who often face anxiety over injections. It is anticipated that the spray will become available in the U.S. within the next eight weeks.